Gastrointestinal Diagnostics Market to Grow at CAGR of 4.65% through 2030
Growing
healthcare infrastructure in emerging markets and rising prevalence of
gastrointestinal disorders is expected to drive the Global Gastrointestinal
Diagnostics Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “Gastrointestinal Diagnostics Market – Global Industry
Size, Share, Trends, Competition, Forecast & Opportunities, 2020-2030F”,
the Global Gastrointestinal Diagnostics Market stood at USD 5.33 Billion in 2024 and
is expected to reach USD 7.02 Billion by 2030 with a CAGR of 4.65% during the
forecast period.
The Global
Gastrointestinal Diagnostics Market is experiencing significant growth due
to a combination of factors including rising awareness of gastrointestinal
diseases, technological advancements in diagnostic tools, increasing prevalence
of gastrointestinal disorders, and the growing demand for early detection and
preventive care. Gastrointestinal disorders, such as colorectal cancer, inflammatory
bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable
bowel syndrome (IBS), are becoming more common worldwide, with changing
lifestyles, poor dietary habits, and an aging population contributing to their
rise. This has created a strong demand for effective diagnostic solutions,
driving the expansion of the gastrointestinal diagnostics market across various
regions.
In developed
regions like North America and Europe, healthcare systems are
well-established, with patients having access to advanced diagnostic
technologies and healthcare services. In these regions, the market is primarily
driven by a higher prevalence of conditions like colorectal cancer and IBD,
which require regular screening and diagnostic procedures. Colonoscopy
remains one of the most widely used diagnostic tools in North America and
Europe for colorectal cancer screening, while endoscopy is crucial for
diagnosing other gastrointestinal conditions. Early detection through these
diagnostic methods has been proven to improve patient outcomes, driving demand
in both the hospital and outpatient settings.
The growing
emphasis on preventive healthcare in these regions is encouraging routine
diagnostic screenings, which in turn is increasing the demand for
gastrointestinal diagnostic tests. With the rise of personalized medicine
and genomic diagnostics, technologies like PCR (Polymerase Chain
Reaction) and molecular diagnostics are being integrated into
clinical practice to provide more accurate and tailored treatment options for
patients. Advancements in AI-based diagnostic tools are expected to
further transform the landscape, enabling quicker and more precise diagnoses
for a wide range of gastrointestinal diseases.
In emerging
markets such as Asia Pacific and South America, the
gastrointestinal diagnostics market is experiencing rapid growth due to
improving healthcare infrastructure, increased healthcare investments, and the
rising prevalence of gastrointestinal conditions, particularly in aging
populations. However, challenges such as affordability, lack of healthcare
access in rural areas, and limited awareness about early diagnosis hinder the
widespread adoption of advanced diagnostic technologies. Despite these challenges,
the increasing number of patients seeking medical attention for
gastrointestinal symptoms and the expanding availability of diagnostic
technologies are expected to drive market growth in these regions.
Asia Pacific, in particular,
is witnessing a rise in the incidence of gastrointestinal disorders due to
changing diets, lifestyle shifts, and environmental factors. Countries like China,
India, and Japan are focusing on enhancing their healthcare
systems to provide better access to diagnostic services. The introduction of
cost-effective diagnostic tests and growing public health initiatives to
promote gastrointestinal disease awareness are expected to support the
expansion of the market in this region.
One of the major
factors driving the global market is the increasing demand for early
detection of gastrointestinal diseases. Conditions like colorectal
cancer, which are asymptomatic in their early stages, can be fatal if not
detected in time. This has led to growing government initiatives and
recommendations for routine screening, especially for at-risk
populations. Endoscopic procedures like colonoscopy and gastroscopy,
alongside non-invasive tests like fecal immunochemical tests (FIT) for
colorectal cancer, are gaining popularity due to their effectiveness in early
diagnosis and prevention.
Technological
advancements in gastrointestinal diagnostics are also a key driver. Artificial
Intelligence (AI) and machine learning algorithms are becoming
increasingly integrated into diagnostic tools, allowing healthcare
professionals to analyze vast amounts of data more efficiently and accurately.
AI-driven endoscopic systems, for example, can assist in detecting
abnormalities such as polyps and tumors more quickly than traditional methods. Capsule
endoscopy, a minimally invasive procedure, is also gaining popularity for
diagnosing diseases in the small intestine, providing patients with a less
invasive alternative to traditional endoscopy.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Gastrointestinal Diagnostics Market”
The Global Gastrointestinal
Diagnostics Market is segmented into test type, technology, application, test
location, regional distribution, and company.
Based on test
location, the Central Laboratories are currently dominating, primarily due to
their ability to handle a wide range of diagnostic tests, including complex,
specialized analyses that require high precision and advanced technology.
Central laboratories are equipped with state-of-the-art infrastructure, highly
skilled technicians, and cutting-edge diagnostic equipment, allowing them to
provide comprehensive testing services for various gastrointestinal conditions
such as colorectal cancer, inflammatory bowel disease (IBD), gastroesophageal
reflux disease (GERD), and hepatitis. These labs are capable of performing a
broad spectrum of tests, including endoscopy, PCR-based tests, biopsy analysis,
and genomic profiling, which are critical for diagnosing complex
gastrointestinal diseases and offering accurate results.
One of the key
factors driving the dominance of central laboratories in the gastrointestinal
diagnostics market is their ability to conduct high-throughput testing. This
allows them to handle large volumes of samples efficiently, which is crucial in
settings such as hospitals, research institutes, and diagnostic centers. These
laboratories also benefit from the integration of advanced technologies such as
artificial intelligence (AI) and machine learning, which aid in analyzing large
amounts of data quickly and accurately, enabling healthcare professionals to
make more informed decisions. This comprehensive approach to diagnostics,
coupled with the high level of accuracy provided by central laboratories, makes
them the preferred choice for complex diagnostic tests. Another factor
contributing to the dominance of central laboratories is their ability to
provide a wide variety of tests beyond standard diagnostic procedures. For
instance, tests for microbial infections, genetic mutations, molecular
diagnostics, and tumor markers are routinely conducted in central laboratories,
helping to detect underlying gastrointestinal conditions that may not be
identified through traditional diagnostic methods. This versatility and
capacity to perform a diverse range of tests make central laboratories
indispensable in the gastrointestinal diagnostics landscape, particularly for
conditions that require specialized tests or multiple levels of analysis.
Based on region,
Europe is the second-largest contributor to the Global
Gastrointestinal Diagnostics Market, following North America. Europe’s
strong healthcare infrastructure, high levels of healthcare investment, and
increasing awareness of gastrointestinal diseases have positioned it as a
leading player in the market. The region benefits from a robust healthcare
system, where governments and private organizations emphasize preventive care
and early diagnosis of conditions such as colorectal cancer, irritable
bowel syndrome (IBS), and inflammatory bowel disease (IBD), which
are prevalent among the European population.
A significant
driver of the gastrointestinal diagnostics market in Europe is the high
incidence of colorectal cancer, one of the leading causes of
cancer-related deaths in the region. The European Union has implemented
screening programs to detect colorectal cancer early, which is contributing to
a surge in demand for endoscopic procedures, such as colonoscopy,
and other diagnostic tools. These screenings are often recommended for
individuals over 50 or those at higher risk, further increasing the need for diagnostic
tests to detect early signs of gastrointestinal diseases. Along with colorectal
cancer, Europe is also witnessing an increase in gastrointestinal disorders
such as gastroesophageal reflux disease (GERD) and gastrointestinal
infections, further driving the demand for diagnostic services. Technological
advancements in the region are also propelling the growth of the market. Artificial
intelligence (AI) and machine learning are being integrated into
gastrointestinal diagnostic tools, particularly in endoscopy procedures,
improving diagnostic accuracy and efficiency. These innovations help healthcare
professionals detect early signs of diseases such as polyps, tumors,
and inflammatory lesions. AI-driven tools are enabling faster analysis
of data, which supports quicker decision-making and enhanced patient outcomes.
This focus on technological innovation has made Europe one of the leading
regions for gastrointestinal diagnostics, with many of the world’s top
diagnostic device manufacturers, research institutions, and healthcare
providers based in countries like Germany, France, and the UK.
Major companies
operating in Global Gastrointestinal Diagnostics Market are:
- bioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories, Inc.
- Beckman Coulter, Inc.
- DiaSorin S.p.A
- Siemens Healthineers AG
- QIAGEN N.V.
- Meridian Bioscience, Inc.
- Hologic, Inc.
- Epitope Diagnostics Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The future of
the Global Gastrointestinal Diagnostics Market looks promising, driven
by advancements in technology, increasing prevalence of gastrointestinal
disorders, and growing awareness of the importance of early detection. The
adoption of minimally invasive techniques like endoscopy, coupled with
innovations such as AI-driven diagnostics and molecular testing,
is expected to enhance diagnostic accuracy and efficiency. Rising demand for
personalized medicine and tailored treatments will further propel market
growth. The aging global population will significantly contribute to the
increased demand for regular screenings and diagnostic procedures. As
healthcare systems focus more on preventive care and improving accessibility,
the gastrointestinal diagnostics market will continue to expand, providing
better diagnostic tools and improving patient outcomes worldwide.,” said Mr.
Karan Chechi, Research Director, TechSci Research, a research-based management
consulting firm.
“Gastrointestinal Diagnostics Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type
(Endoscopy, Blood Test, H. pylori Test, Calprotectin Test, Immunoglobulin A
Test, and Others), By Technology (ELISA, PCR, Microbiology, and Others), By Application
(Infection, Inflammatory Bowel Disease, Gastroesophageal Reflux Disease,
Cancer, and Others), By Test Location (Central laboratories and Point-of-Care),
By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Gastrointestinal Diagnostics Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Gastrointestinal Diagnostics Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com